Glaukos Corporation

NYSE:GKOS

Medical - Devices

Healthcare
$233.08 -0.14%

-$0.18 today

Market cap
$13.80B
Beta
0.81
P/E (TTM)
-39.0
EPS (TTM)
-$3.26
52W Low $73.16High $148.11

Volume 1.12M

Average 0.94M

GKOS Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Glaukos CorporationNYSE: GKOS

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents rises 13.6% from a year ago

Cash & equivalents stood at $114.49M at the end of Q2 FY2026, up 13.6% from a year earlier and up 9.8% from the prior quarter. Over 3 fiscal years it compounded at -8.8% a year.

Context

  • Cash & equivalents amounted to 12.4% of total assets at the end of Q2 FY2026, up 2.2 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +13.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$114.49M+9.8% QoQ
Last fiscal yearDec 2025
$90.81M-46.5% YoY
Year agoJun 2025
$100.81M+13.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.6%——
1 year-46.5%——
3-year CAGR-8.8%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
90.81M USD
Year-over-year change
-46.5%
4-year CAGR
-2.6%

Cash & Equivalents vs competitors

How GKOS compares with its peers on the latest reported figures

  • GKOS's Jun 2026 cash & equivalents of $114.49M is the 6th highest of the 9 companies compared; the peer median is $185.38M.
  • Its year-over-year change of +13.6% is the 4th highest of 8, against a peer median of -8.7%.
  • Cash & equivalents amounts to 12.4% of total assets for GKOS, versus a peer median of 28.1%.
GKOS Competitors Peer median
Cash & Equivalents for GKOS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALCAlcon Inc.Sep 2026$1.71B +13.9%+15.9%5.4%
OCULOcular Therapeutix, Inc.Mar 2026$666.7M +90.7%+93.1%91.0%
BLCOBausch + Lomb CorporationJun 2026$367M +34.9%+0.3%2.6%
SGPSpyGlass Pharma, Inc. Common StockMar 2026$238.9M ——92.5%
STAASTAAR Surgical CompanyApr 2026$131.86M -23.8%+21.0%29.2%
GKOSGlaukos CorporationJun 2026$114.49M +13.6%-8.8%12.4%
SGHTSight Sciences, Inc.Mar 2026$84.96M -21.9%-20.8%77.4%
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026$77.71M -8.7%+2.1%27.0%
RXSTRxSight, Inc.Mar 2026$17.57M -37.2%+19.0%5.8%
Peer median (excluding GKOS) $185.38M-8.7%+15.9%28.1%

Competitors are the stored peer set for GKOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents100.71M119.53M93.47M169.63M90.81M
Short-term Investments313.34M233.17M201.96M149.29M187.95M
Net Receivables33.44M36.07M39.85M60.74M108.61M
Inventory23.01M37.84M41.99M57.68M63.56M
Other Current Assets15.63M17.25M18.19M12.46M24.05M
Total Current Assets486.13M443.86M395.46M449.79M474.98M
Property, Plant & Equipment (Net)146.13M166.83M174.54M169.94M184.18M
Goodwill66.13M66.13M66.13M66.13M66.71M
Intangible Assets332.78M307.87M282.96M263.45M141.92M
Long-term Investments9.42M7.08M003.83M
Tax Assets79.13M71.79M000
Other Non-current Assets9.11M10.61M21.33M25.45M21.86M
Total Non-current Assets642.7M630.31M544.95M524.96M418.5M
Total Assets1.13B1.07B940.41M974.76M893.49M
Account Payables7.33M14.4M13.44M13.03M24.62M
Short-term Debt1.01M430K000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities33.81M35.83M20.59M24.87M76.65M
Total Current Liabilities63.36M72.36M74.01M75.13M101.28M
Long-term Debt280.03M281.4M282.77M035.77M
Deferred Tax Liabilities86.45M79.05M7.14M6.93M441K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities9.49M10.28M13.75M22.37M(4.03M)
Total Non-current Liabilities478.32M471.8M404.63M132.7M136.06M
Total Liabilities541.68M544.16M478.65M207.83M237.33M
Common Stock47K48K49K56K58K
Retained Earnings(365.21M)(464.41M)(599.07M)(745.44M)(933.13M)
Accumulated OCI15K(2.98M)1.17M2.62M3.3M
Other Stockholders Equity00000
Minority Interest00000
Total Equity587.15M530.01M461.77M766.93M656.16M
Total Debt383.39M382.91M383.74M103.4M139.64M
Net Debt282.68M263.38M290.27M(66.23M)48.83M

Glaukos Corporation

NYSE:GKOS

Intrinsic Alpha fair value

Locked

Current Price

$233.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.